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Abstract With the ultimate aim of developing an effective
antiviral strategy against HIV-1, a mono-DNA enzyme posses-
sing the 10^23 catalytic motif [Santoro and Joyce (1997) Proc.
Natl. Acad. Sci. USA 94, 4264^4266] was synthesized against
the HIV-1 envelope gene. We tested the in vitro cleavage
efficiency of the 178 bp long truncated HIV-1 Env transcript by
DNA enzyme 6339. Protein independent and Mg2+ dependent
specific cleavage products were obtained. As soon as 5 min after
mixing equimolar concentrations of DNA enzyme and substrate
RNA, more than 50% cleavage was observed which increased
steadily over a period of 4 h. Very little cleavage was obtained at
1 mM MgCl2 concentration which improved significantly when
the concentration of MgCl2 was increased up to 20 mM. Specific
inhibition of cell membrane fusion caused by the interaction of
gp160 and CD4 in HeLa cells was observed when the above DNA
enzyme was used. Thus, these chemically synthesized DNA
enzymes could prove to be very useful for in vivo application.
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1. Introduction
The antisense approach is currently being used for speci¢c
down regulation of a target gene for the treatment of many
diseases and disorders. Often administration of large amounts
of the antisense oligonucleotides (phosphothiorate form) is
required which usually leads to toxicity problems [1]. Ribo-
zymes, being catalytic in nature [2^4] and having the potential
to cleave a target gene (for review [5^7]), have provided new
hope for achieving speci¢c down regulation of the target gene
without causing much toxicity. Indeed several mono- and
multi-target ribozymes [8^14] have been constructed which
showed speci¢c interference of viral or cellular genes. Exoge-
nous application of ribozymes has been a problem because the
RNA is very susceptible to degradation inside the cell and
e¡orts are being made to improve the intracellular stability
of modi¢ed nucleotides [15]. Recently, general purpose RNA-
cleaving DNA enzymes have been described which were
shown to be functional under simulated physiological condi-
tions and the sequences of the two catalytic motifs, 10^23 and
8^17, were reported [16]. Extreme susceptibility of RNA to
intracellular degradation was overcome to quite an extent as
the DNA is more stable inside the cell. These DNA enzymes
are catalytic in nature and can be engineered to cleave a target
gene in trans in a sequence speci¢c manner in presence of
Mg2. Besides, they provide more £exibility for the selection
of cleavage sites. We constructed a mono-DNA enzyme by
targeting an internal AUG sequence (A being the 6339th nu-
cleotide in the pNL4-3 sequence [17]). This AUG (not read as
methionine) is present in the coding region of the envelope
gene (see Fig. 1). This target site is, therefore, di¡erent from
what was selected earlier [16]. Another important distinction
is that we used a 180 bases long HIV-1 envelope transcript for
cleavage which is physiologically more relevant than the syn-
thetic 17 nucleotides long synthetic gene spanning the initia-
tion codon (AUG) of the HIV-1 envelope gene reported ear-
lier [16]. In this communication we show speci¢c in vitro
cleavage of the truncated HIV-1 Env gene of HIV-1 by tar-
geted DNA enzyme and demonstrate its ability to interfere
with the functional expression of the HIV-1 envelope gene
in a cell fusion assay.
2. Materials and methods
2.1. Plasmid DNAs and in vitro synthesis of RNAs
HIV-1 envelope gene (from III B) was placed under T7 promoter
[18] and speci¢c 32P-UTP labeled transcripts (full length and truncated
variants) were generated after linearizing the plasmid with an appro-
priate restriction enzyme according to the manufacturer’s direction
(Promega Biotech, WI, USA) and as described before [19] using T7
RNA polymerase. The steps starting from linearizing the supercoiled
plasmid DNA to obtaining the cleaved products of the substrate RNA
are diagrammatically shown in Fig. 2. Speci¢c activity of the labeled
RNA was determined by standard procedures. These RNAs were
resolved in a 7% polyacrylamide-7 M urea gel using the mini-protein
gel apparatus from Bio-Rad.
2.2. Construction of DNA enzyme
Twenty-nine nucleotides long DNA was synthesized in a DNA
synthesizer (Applied Biosystems). The exact sequence of the target
gene and the sequence of the DNA enzyme together with the regions
speci¢cally hybridizing with substrate RNA and DNA enzyme 6339
are shown in Fig. 1. Seven nucleotides on either side were made
complementary to the target gene and the A nucleotide of the target
gene was left unpaired and cleavage is expected to take place after the
A nucleotide. The earlier identi¢ed catalytic motif (10^23) was placed
between the two antisense £anks which possessed the following se-
quence: 5P-GGCTAGCTACAACGA-3P.
2.3. In vitro cleavage reaction
Equimolar concentrations (100 pmol each) of the 32P labeled sub-
strate RNA and cold DNA enzyme were mixed in 10 Wl of 50 mM
Tris-HCl, pH 7.5, containing varying amounts of MgCl2 (range 1^20
mM). Samples were heated at 95‡C for 2 min before addition of
MgCl2 followed by 1 h incubation at 37‡C. The cleavage products
were analyzed as described before using Tris-Borate-EDTA bu¡er.
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2.4. Analysis of kinetic parameter of DNA enzyme
Kinetic parameters (Km, kcat) of the DNA enzyme 6339 were de-
termined using 32P-UTP labeled truncated HIV-1 envelope RNA, (178
bases long RNA generated by linearizing HIV-1 envelope plasmid by
NdeI) in the presence of excess amounts of DNA enzyme using the
cleavage conditions described earlier. The same restriction site was
earlier used by one of us to synthesize HIV-1 envelope RNA (sub-
strate RNA) to test the cleavage potential of our multitarget ribozyme
against the HIV-1 envelope gene [8].
2.5. Construction of antisense devoid of catalytic motif of DNA enzyme
This was synthesized chemically in a similar manner as other oli-
gonucleotide except the 15 bases corresponding to the catalytic motif
were omitted. The antisense had the following sequence: 5P- TACCC-
CAAATAGAC. In this construction also the A nucleotide of the
target gene was left unpaired.
2.6. Inhibition of HIV-1 envelope-CD4 mediated cell fusion by
DNA enzyme
This was carried out by HIV-1 envelope and CD4 mediated cell
membrane fusion assay as described initially by [20,21] and described
in detail by us recently [22]. The HIV-1 envelope gene was cotrans-
fected with 0.01 Wg of DNA enzyme and T7-HIV-1 Env DNA along
with the reporter gene under T7 promoter (T7-luciferase), which was
fused with HeLa cells expressing CD4 glycoprotein (by DNA trans-
fection) and infected with VTf-7. Recombinant vaccinia virus express-
ing T7 RNA polymerase [23] was used to drive the expression of the
luciferase gene which was also placed under T7 promoter. In this kind
of assay system only fusion dependent reporter gene activation is
measured and the level of reporter gene expression is directly propor-
tional to the extent of cell fusion. Recombinant vaccinia virus was
grown in HeLa cells and puri¢ed according to the method described
by Joklik [24] and as described before [25].
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Fig. 1. Sequence of the target site in the HIV-1 envelope gene with
the cleavage site (6339 nt). Also shown is the sequence of the DNA
enzyme 6339 and the strategy to provide sequence speci¢c cleavage.
Seven bases on either side of the nucleotide AUG are synthesized
complementary to the target gene (A nucleotide is left unpaired).
This DNA enzyme possesses the earlier identi¢ed 10^23 catalytic
motif [16].
Fig. 2. In vitro synthesis of 32P-UTP labeled 178 bases long HIV-1 RNA transcript using HIV-1 envelope plasmid DNA. The plasmid DNA
was linearized with NdeI and subjected to in vitro transcription (Promega Biotech) using T7 RNA polymerase. An equimolar concentration of
DNA enzyme (cold) was added and the cleavage reaction was initiated by adding varying concentrations of MgCl2 and heating at 90‡C for 3
min followed by incubation at 37‡c for 1 h. The cleaved products were subjected to analysis on 7% 7 M urea-SDS-PAGE analysis. After cleav-
ing the substrate RNA, the DNA enzyme is available to act on other substrate molecules and repeat the cycle.
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3. Results
3.1. In vitro cleavage of the 178 bp HIV-1 Env transcript
by DNA enzyme
32P-UTP labeled transcript (178 nt long) was synthesized by
the NdeI digested HIV-1 envelope DNA (Fig. 3, lane 1) by T7
RNA polymerase. 100 pmol of target RNA and DNA enzyme
were added in the presence of 1 mM MgCl2, heated at 90‡C
for 3 min followed by incubation for 1 h at 37‡C in the
presence of varying amounts of MgCl2. No cleavage was ob-
served in the absence of Mg2 (data not shown) and very little
cleavage was seen at 1 mM MgCl2 concentration (lane 2). The
cleavage e⁄ciency increased dramatically to the extent of 50^
80% at concentrations of 5, 10, 15 and 20 mM MgCl2, which
correspond to lanes 3, 4, 5 and 6 respectively. No cleavage of
the substrate RNA was observed when equivalent amounts of
unrelated DNA enzyme were used or the antisense nucleotides
(14 bases long which lacked only the catalytic motif) (data not
shown). The fact that speci¢c cleavage was seen at 1 mM
MgCl2 is a signi¢cant ¢nding because more cleavage would,
in principle, be obtained at 2 mM MgCl2 which is the most
likely concentration at physiological levels [16]. The speci¢city
of cleavage of the Env RNA was further con¢rmed as DNA
enzymes (possessing the same catalytic motif 10^23), when
targeted for other regions of HIV (Nef and gag), failed to
show any activity (data not shown).
3.2. Kinetics of the cleavage reaction
More than 50% speci¢c cleavage was seen by the DNA
enzyme 15 min after the cleavage reaction (Fig. 4, lane 3).
Cleaved 5P (118 nt) and 3P (60 nt) products could be seen as
early as 5 min after the DNA enzyme interaction (lane 2). The
extent of cleavage increased signi¢cantly at 15 min and be-
yond (lanes 3^7). Complete cleavage of the input substrate
was not achieved even after 4 h of incubation (Figs. 4 and
5). The kinetic parameters were very similar to what has been
reported earlier for ribozymes and DNA enzymes [16,26]. The
Km and kcat values for this DNA enzyme 6339 are presented
in Table 1. They are 0.416 nM and 0.763 min31 and the ratio
of kcat over Km was 1.83U109 M31 min31.
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Fig. 3. E¡ect of magnesium chloride concentration on the cleavage
activity. Labeled HIV-1 envelope transcript (178 bases long) was
synthesized as described before and equimolar amounts of cold
DNA enzyme were added in the presence of varying amounts of
MgCl2. The mixture was heated at 90‡C for 3 min followed by 1 h
incubation at 37‡C and subjected to gel electrophoretic analysis as
described before. Lane 1 shows the labeled transcript (178 bases)
synthesized from the HIV-1 Env DNA that was linearized with
NdeI. Very little cleavage of the substrate RNA was achieved in the
presence of 1 mM MgCl2 (lane 2) but cleavage increased signi¢-
cantly at 5 mM (lane 3), 10 mM (lane 4), 15 mM (lane 5) and 20
mM (lane 6). Also no cleavage was observed in any of these experi-
mental conditions if the magnesium chloride was omitted from the
cleavage reaction bu¡er (data not shown).
Table 1
Kinetic analysis of DNA enzyme 6339
Km (nM) kcat (min31) kcat/Km (M31 min31)
0.416 0.763 1.83U109
Kinetic measurements were carried out for the DNA enzyme 6339 by
taking varying amounts of labeled substrate RNA in 50 mM Tris-HCl
pH 7.5 and 10 mM MgCl2 under DNA enzyme saturating conditions
at 37‡C for 1 h. The substrates and the cleaved products were sepa-
rated on 7% polyacrylamide-7 M urea gels and detected by autora-
diography of the dried gels. The extent of cleavage was determined by
quantitating the radioactivity present in each band with the help of a
phosphorimager. The kinetic parameters were calculated from a Line-
weaver-Burk plot. Rate constants are averages from two separate
experiments.
Fig. 4. Kinetics of the cleavage of HIV-1 envelope gene by DNA
enzyme 6339. A: Equimolar concentrations of substrate and DNA
enzyme were mixed and the cleavage reaction was initiated as de-
scribed above for varying lengths of time (5 min to 4 h). Lane 1 de-
picts the synthesis of labeled HIV-1 envelope transcript (178 bases
long). Lanes 3, 4, 5, 6 and 7 show the extent of cleavage achieved
after 15 min, 30 min, 60 min, 120 min and 240 min respectively.
Signi¢cant cleavage was obtained after 5 min of interaction (lane 2),
which increased to more than 80% when the reaction was carried
out for an extended period of time (B).
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3.3. Inhibition of cell membrane fusion by DNA enzyme
Signi¢cant inhibition of fusion was observed with Dz 6339
but an equivalent amount of unrelated DNA enzyme (targeted
to cleave the X gene of hepatitis B) failed to show any inhib-
ition (Fig. 5). The sequence of the DNA enzyme that was
targeted to cleave the 307 nt of the X gene [27] of hepatitis
B (abbreviated as HBx-Dz-307) virus was as follows: 5P-
GTTGACAGGCTAGCTACAACGATGCTGGGG-3P. The
catalytic motif is the same as before and is shown in bold
letters. This was used as a control DNA enzyme for the
sake of comparison under identical experimental conditions.
A similar pattern of inhibition was achieved with two other
ratios of HIV-1 Env DNA and DNA enzyme (0.05 Wg and
0.10 Wg each; data not shown). No toxicity towards HeLa
cells was observed at these concentrations of plasmid DNAs
or oligonucleotides.
4. Discussion
We have shown precise cleavage of a 178 bases long HIV-1
envelope transcript and inhibition of the functional expression
of HIV-1 envelope by cell fusion assays. It can be argued that
the observed inhibition of the cell membrane could be due to
the antisense £anks (14 bases altogether) of the DNA en-
zymes. We ruled out that possibility to a great extent by
synthesizing a 14 bases long oligonucleotide (5P-TACCC-
CAAATAGAC) which lacked the catalytic motif but retained
the antisense £anks. Only 10^15% speci¢c inhibition was ob-
served under similar experimental conditions (data not
shown). We conclude that the observed inhibition by this
DNA enzyme was most likely because of the catalytic cleav-
age of the HIV-1 Env RNA. Although we presented targeted
in vitro cleavage of 178 bases long HIV-1 RNA transcript
(obtained by digesting the HIV-1 envelope DNA by NdeI)
by the DNA enzyme 6339 and showed its ability to interfere
with the functional expression of HIV-1 envelope gene in a
cell fusion assay, in vitro cleavage of longer HIV-1 envelope
transcripts (819 and 1916 bases long transcripts generated by
linearizing the HIV-1 envelope DNA with BglII and HindIII
restriction enzyme digestions respectively) by this DNA en-
zyme was also observed but, as expected, the e⁄ciency of
the cleavage decreased with increasing size of the substrate
RNA (data not shown). As was previously observed [16],
the DNA enzyme described in this manuscript possessed a
catalytic e⁄ciency (kcat/Km) of V109 M31 min31 under multi-
ple turnover conditions.
Our data strongly suggest that these DNA enzymes could
prove to be a valuable tool to selectively down regulate HIV
replication or alternatively cleave any RNA (cellular or from
any pathogen) and should be explored for therapeutic poten-
tial. Multitarget DNA enzymes could be used to cleave the
target gene at multiple speci¢c sites. This is especially impor-
tant if the target gene is known to accumulate mutations.
Most RNA viruses, including HIV-1, are known to mutate
at an extraordinary rate after treatment with anti-retroviral
drugs. Using this approach together with other treatment mo-
dalities, it may be possible to signi¢cantly delay the appear-
ance of the resistant population of viruses.
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